Tech Company Financing Transactions

Reata Pharmaceuticals Funding Round

Cardinal Venture Capital and Novo Ventures participated in a $22.6 million venture round for Reata Pharmaceuticals. The round was announced on 8/4/2006.

Transaction Overview

Company Name
Reata Pharmaceuticals
Announced On
8/4/2006
Transaction Type
Venture Equity
Amount
$22,600,000
Round
Undisclosed
Investors

Cardinal Venture Capital (Lead Investor) (Kent McGaughy)

Novo Ventures (Jack Nielsen)

Proceeds Purpose
Capital raised in the current financing round will be used to (i) initiate advanced clinical studies with RTA 744, (ii) conduct additional Phase 2 studies with RTA 401/402, (iii) develop commercially viable manufacturing processes and formulations for Reata's advanced drug candidates, and (iv) identify small molecule chaperones that can induce proper folding of p53, SOD, and Tau, misfolded proteins that are involved in cancer and neurodegenerative disease.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
2801 Gateway Dr. 150
Irving, TX 75063
USA
Phone
(972) 865-2219
Website
www.reatapharma.com
Email Address
[email protected]
Overview
Reata Pharmaceuticals, Inc. (NASDAQ: RETA) is a biopharmaceutical company focused on developing novel treatments for cancer, inflammation, and neurodegenerative diseases.
Profile
Reata Pharmaceuticals LinkedIn Company Profile
Social Media
Reata Pharmaceuticals Company Twitter Account
Company News
Reata Pharmaceuticals News
Facebook
Reata Pharmaceuticals on Facebook
YouTube
Reata Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Warren Huff
  Warren Huff LinkedIn Profile  Warren Huff Twitter Account  Warren Huff News  Warren Huff on Facebook
Chief Financial Officer
Jason Wilson
  Jason Wilson LinkedIn Profile  Jason Wilson Twitter Account  Jason Wilson News  Jason Wilson on Facebook
Chief Medical Officer
Colin Meyer
  Colin Meyer LinkedIn Profile  Colin Meyer Twitter Account  Colin Meyer News  Colin Meyer on Facebook
VP - Bus. Development
Dawn Bir
  Dawn Bir LinkedIn Profile  Dawn Bir Twitter Account  Dawn Bir News  Dawn Bir on Facebook
VP - Bus. Development
Keith Ward
  Keith Ward LinkedIn Profile  Keith Ward Twitter Account  Keith Ward News  Keith Ward on Facebook
VP - Finance
Elaine Castellanos
  Elaine Castellanos LinkedIn Profile  Elaine Castellanos Twitter Account  Elaine Castellanos News  Elaine Castellanos on Facebook
VP - General Counsel
Michael Wortley
  Michael Wortley LinkedIn Profile  Michael Wortley Twitter Account  Michael Wortley News  Michael Wortley on Facebook
VP - Marketing
David Chapman
  David Chapman LinkedIn Profile  David Chapman Twitter Account  David Chapman News  David Chapman on Facebook
VP - R & D
Christian Wigley
  Christian Wigley LinkedIn Profile  Christian Wigley Twitter Account  Christian Wigley News  Christian Wigley on Facebook
VP - Regulatory Affairs
Joel Proksch
  Joel Proksch LinkedIn Profile  Joel Proksch Twitter Account  Joel Proksch News  Joel Proksch on Facebook

 

 

Browse more venture capital transactions:

Prev: 8/3/2006: CaseRev venture capital transaction
Next: 8/7/2006: EverNote venture capital transaction

 

Share this article

 

About Our Venture Capital Transactions Database

We do our best to report on tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.